These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 2871243)
21. [CLINICAL IMPLEMENTATION OF CELL-FREE DNA ANALYSIS IN MATERNAL BLOOD IN SCREENING FOR ANEUPLOIDIES IN SINGLETON PREGNANCIES]. Chaveeva P; Yankova M; Stratieva V; Dimitrov I; Shterev A Akush Ginekol (Sofiia); 2016; 55(2):10-5. PubMed ID: 27509651 [TBL] [Abstract][Full Text] [Related]
22. [Combined use of nuchal translucency, gestational age and maternal age for evaluation of the risk of trisomy 21]. Faraut T; Cans C; Althuser M; Jouk PS J Gynecol Obstet Biol Reprod (Paris); 1999 Sep; 28(5):439-45. PubMed ID: 10566163 [TBL] [Abstract][Full Text] [Related]
23. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Bindra R; Heath V; Liao A; Spencer K; Nicolaides KH Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441 [TBL] [Abstract][Full Text] [Related]
24. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Santorum M; Wright D; Syngelaki A; Karagioti N; Nicolaides KH Ultrasound Obstet Gynecol; 2017 Jun; 49(6):714-720. PubMed ID: 27549925 [TBL] [Abstract][Full Text] [Related]
25. Down syndrome rates and relaxed selection at older maternal ages. Hook EB Am J Hum Genet; 1983 Nov; 35(6):1307-13. PubMed ID: 6228139 [TBL] [Abstract][Full Text] [Related]
26. Maternal Age-Specific Rates for Trisomy 21 and Common Autosomal Trisomies in Fetuses from a Single Diagnostic Center in Thailand. Jaruthamsophon K; Sriplung H; Charalsawadi C; Limprasert P PLoS One; 2016; 11(11):e0165859. PubMed ID: 27812158 [TBL] [Abstract][Full Text] [Related]
28. Trisomy recurrence: a reconsideration based on North American data. Warburton D; Dallaire L; Thangavelu M; Ross L; Levin B; Kline J Am J Hum Genet; 2004 Sep; 75(3):376-85. PubMed ID: 15248154 [TBL] [Abstract][Full Text] [Related]
29. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579 [TBL] [Abstract][Full Text] [Related]
30. Recurrences of trisomy 18 and trisomy 13 after trisomy 21. FitzPatrick DR; Boyd E Hum Genet; 1989 Jun; 82(3):301. PubMed ID: 2525109 [TBL] [Abstract][Full Text] [Related]
31. Maternal age-specific risk for trisomy 21 based on the clinical performance of NIPT and empirically derived NIPT age-specific positive and negative predictive values in Japan. Yamada T; Sekizawa A; Fujii Y; Hirose T; Samura O; Suzumori N; Miura K; Sawai H; Hirahara F; Murotsuki J; Kamei Y; Sago H; J Hum Genet; 2018 Oct; 63(10):1035-1040. PubMed ID: 29849041 [TBL] [Abstract][Full Text] [Related]
33. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Wright D; Syngelaki A; Bradbury I; Akolekar R; Nicolaides KH Fetal Diagn Ther; 2014; 35(2):118-26. PubMed ID: 24356462 [TBL] [Abstract][Full Text] [Related]
34. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635 [TBL] [Abstract][Full Text] [Related]
35. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371 [TBL] [Abstract][Full Text] [Related]
36. [Screening for congenital anomalies in mid-term pregnancy. Prospective epidemiologic study. Fetal trisomy]. Tóth-Pál E; Oroszné Nagy J; Papp C; Szabó M; Veress L; Török O; Tóth Z; Papp Z Orv Hetil; 1995 Feb; 136(9):483-9. PubMed ID: 7535413 [TBL] [Abstract][Full Text] [Related]
37. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Sarno L; Revello R; Hanson E; Akolekar R; Nicolaides KH Ultrasound Obstet Gynecol; 2016 Jun; 47(6):705-11. PubMed ID: 26970114 [TBL] [Abstract][Full Text] [Related]
38. [Down syndrome in the northeastern Netherlands; expectations and reality 1981-1986]. Cornel MC; Tuerlings JH; Breed AS; ten Kate LP Ned Tijdschr Geneeskd; 1990 Sep; 134(38):1852-5. PubMed ID: 2145518 [TBL] [Abstract][Full Text] [Related]
39. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting. Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470 [TBL] [Abstract][Full Text] [Related]
40. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N; J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]